Chinese Researchers Transplant Stem Cell-Derived Islets in Type 1 Diabetes Patients

Researchers at the Chinese Academy of Sciences' Centre for Excellence in Molecular Cell Science have developed a new method to create pancreatic islet tissue from stem cells. According to a study published in The Lancet Diabetes & Endocrinology, the team successfully transplanted this tissue into three patients with type 1 diabetes.

The new approach is based on a key difference: instead of using pluripotent stem cells—which can become any cell type in the body—the researchers used endoderm stem cells that are already partway along the developmental path toward becoming islet cells. This shortcut bypasses much of the lengthy cultivation process required by traditional methods.

Creating pancreatic islets from pluripotent stem cells typically involves a long, complex process of coaxing cells through multiple developmental stages in the laboratory. This "branching" process can take 40 days or longer and often produces unwanted cell types alongside the target cells.

By starting with endoderm stem cells instead, researchers reduced the cultivation time to just 14 days. Cheng Xin, a co-corresponding author on the paper, explained the concept simply: "Our approach is like replacing a 'part' for the patient."

An additional potential advantage is safety: endoderm stem cells do not proliferate once transplanted into the body, which may lower the risk of tumor formation—a theoretical concern with some stem cell therapies.

This report describes results from three patients, representing an important early proof-of-concept. However, much more research is needed before conclusions can be drawn about whether this approach will work widely or safely across larger populations.

The findings suggest that stem cell-derived islet transplantation may one day offer an alternative to lifelong insulin injections for people with type 1 diabetes. For now, this remains a promising experimental approach being studied by researchers worldwide.

Origin: sinardaily.my (News report). Evidence: News report — unverified, pending corroboration. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.